| Ytd | 35.48% | |
| 1y | -13.85% |
| Open | 1.71 | Prev Close | 1.73 | Low | 1.68 | High | 1.80 | Mkt Cap | 121.77M |
| Vol | 1.02M | Avg Vol | 1.08M | EPS | -0.18 | P/E | N/A | Forward P/E | -1.21 |
| Beta | -0.43 | Short Ratio | 12.98 | Inst. Own | 64.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 1.33 | 200-d Avg | 1.36 | 1yr Est | 40.56 |
BMEA News
Shares of Biomea Fusion Inc (NASDAQ:BMEA) are trading sharply higher on Monday following an operatio
Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess
SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion”
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts revea
• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semag
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst co
SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusio
Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preserv
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservati
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on P
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on P
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.17) per share which beat the analyst co
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinic
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit
Citizens analyst Jonathan Wolleben initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Marke
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusi
Biomea Fusion, Inc. (NASDAQ: BMEA - Get Free Report) has been given a consensus rating of "Moderate
Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:B
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II en
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabete
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Anta
Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and raises t
SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusi
Biomea Fusion (NASDAQ: BMEA - Get Free Report) is anticipated to announce its Q4 2025 results before
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data fo
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint
Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (Nasdaq: BM
Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers t
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lower
Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (Nasdaq: BM
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.27) per share which missed the analyst
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint
Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company,
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company,
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in t
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint
